Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Conditions

• Ulcerative Colitis

Eligibility Criteria

Sex

ALL

Age

2 Years - 17 Years

Healthy Volunteers

Not accepted

Interventions

• Upadacitinib — DRUG
  Oral Solution/ Tablets

Study Details

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: an 8-week open-label induction phase which means that the study doctor and patients know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 44-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 260 week open-label extension (OLE) of Period 1. Approximately 110 pediatric participants with moderate to severely active UC will be enrolled at up to 100 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will be followed up for 30 days after each phase (i.e. after induction, maintenance, OLE) and only if a participant doesn't continue into the next phase. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Key Dates

Start date

Nov 6, 2023

Status verified

May 2026

Primary completion

Aug 31, 2028

Completion

Oct 31, 2031

Study Design

Enrollment

122 participants (actual)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Period 1- Open Label Induction Phase
  All participants in open label induction phase of Period 1 will receive upadacitinib Dose A for 8 weeks based on body weight.
• Experimental: Period 1- Double Blind Maintenance Phase
  Clinical responders at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose B or Dose C for 44 weeks based on body weight.
• Experimental: Period 2- Open Label Long Term Extension Phase Arm A
  Clinical non-responders outside of US after Period 1 induction phase will receive upadacitinib Dose A daily for 8 week extended induction phase in open label long term extension (OLE) Period 2. Clinical responders from extended induction phase in OLE will receive upadacitinib Dose B daily for up to 252 weeks in OLE period 2.
• Experimental: Period 2- Open Label Long Term Extension Phase Arm B
  Clinical non-responders in US after Period 1 induction phase or clinical responders with loss of response during maintenance phase will receive upadacitinib Dose B daily for up to 260 weeks in OLE Period 2.
• Experimental: Period 2- Long Term Extension Phase Arm C
  Clinical responders who complete Period 1 through Week 52 will receive upadacitinib Dose C daily for up to 260 weeks in OLE Period 2.

Primary Outcome Measure

Percentage of Participants Achieving Adapted Mayo score (AMS) Clinical Remission (Period 1) [ Time Frame: Week 8 ]

Locations (20)

Find similar trials in Phoenix, AZ

Related Studies

• Fecal Microbiome Transplant
  PHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania
• Improving the Quality of Care for Adults With Inflammatory Bowel Disease
  Enrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
• The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
  Recruiting · Stanford University · Palo Alto, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama